What is the Hamilton Anxiety Rating Scale?

The Hamilton Anxiety Rating Scale (HAM-A) is a 14-item clinician-rated scale developed by Max Hamilton in 1959 to measure anxiety severity across psychic (cognitive/psychological) and somatic (physical) anxiety domains. It is the most widely used primary endpoint in clinical trials of anxiolytic medications.

How is the HAM-A scored?

A trained clinician rates each of 14 items from 0 (absent) to 4 (very severe) based on structured patient interview. Total score range is 0-56. Score bands: ≤17 = mild anxiety; 18-24 = mild to moderate; 25-30 = moderate to severe; ≥31 = severe anxiety.

What does a HAM-A score mean for treatment?

HAM-A guides treatment intensity and monitors response. Response is defined as ≥50% reduction from baseline; remission as ≤7 or ≤10 depending on protocol. A 7-point change represents the minimum clinically important difference (MCID) for meaningful improvement.

Is HAM-A self-reported by patients?

No. HAM-A requires trained clinician administration based on structured interview and observation. Self-administration produces invalid results. For patient self-report anxiety assessment, use GAD-7 (validated self-report) which has largely replaced HAM-A in routine clinical practice.

How does HAM-A differ from GAD-7?

HAM-A: 14 items, clinician-rated, captures both psychic and somatic anxiety, primary use in clinical trials. GAD-7: 7 items, patient self-report, widely validated for screening and monitoring in primary care. GAD-7 is preferred in clinical practice; HAM-A is preferred in research contexts requiring standardized clinician ratings.

What is first-line treatment for generalized anxiety disorder?

First-line GAD treatment includes SSRIs (sertraline, escitalopram), SNRIs (duloxetine, venlafaxine), and cognitive behavioral therapy (CBT). Combination pharmacotherapy plus CBT typically produces the best outcomes. HAM-A is used to measure response to these treatments in clinical trials.

What are the HAM-A psychic and somatic subscales?

HAM-A has two subscales: Psychic anxiety (items 1-6: anxious mood, tension, fears, insomnia, concentration, depressed mood) capturing cognitive and emotional anxiety, and Somatic anxiety (items 7-13: muscular, sensory, cardiovascular, respiratory, GI, genitourinary, autonomic symptoms) capturing physical manifestations of anxiety.

Can HAM-A be affected by medical comorbidities?

Yes. HAM-A somatic items (cardiovascular palpitations, GI upset, sweating) can be elevated in physically ill patients due to medical conditions rather than anxiety. This is a significant limitation in medically ill populations; clinicians must interpret somatic items in context of the patient's medical history.

What is the MCID for HAM-A?

The minimum clinically important difference (MCID) for HAM-A is approximately 7 points, representing a meaningful change in anxiety severity that exceeds measurement noise. Treatment response is conventionally defined as ≥50% reduction from baseline total score.

What are alternatives to benzodiazepines for anxiety?

Evidence-based alternatives include: SSRIs/SNRIs (first-line, non-addictive), buspirone (5-HT1A agonist, non-addictive but slower onset), hydroxyzine (antihistamine, non-addictive, useful short-term), pregabalin (GABAergic, limited dependence), and cognitive behavioral therapy (CBT). These are preferred over long-term benzodiazepines.

How is HAM-A used in clinical trials?

HAM-A is typically a primary or key secondary endpoint in GAD and anxiety disorder clinical trials. Trials require: certified rater training, inter-rater reliability assessments, blinded administration, and standardized scoring procedures. FDA guidance for anxiety disorder drug development specifies HAM-A as an acceptable primary endpoint.

What training is required to administer HAM-A?

Accurate HAM-A administration requires training in the standardized interview procedure, familiarity with anxiety disorder phenomenology, and understanding of item anchor descriptions. In research settings, raters undergo formal certification including video rating exercises and calibration sessions. Clinical use requires at minimum a structured interview approach.

Online Medical Tools — HAM-A

Printed on 9/4/2026

For informational purposes only. This is not medical advice.

Mental Health

HAM-A

HAM-A is a clinician-rated anxiety severity instrument scoring psychic and somatic anxiety domains across 14 items, each rated 0 to 4.

Formula: HAM-A total = sum of 14 item scores (0-56).

Anxious mood

Tension

Fears

Insomnia

Intellectual (concentration/memory)

Depressed mood

Somatic (muscular)

Somatic (sensory)

Cardiovascular symptoms

Respiratory symptoms

Gastrointestinal symptoms

Genitourinary symptoms

Autonomic symptoms

Behavior at interview

Save your results with a free account

Keep a history of calculations, favorite tools, and access your dashboard anytime.

Create free account Sign in

How It Works

Clinician Rates 14 Items Based on Patient Interview

A trained clinician rates each of 14 items covering psychic anxiety (items 1-7: anxious mood, tension, fears, insomnia, concentration, depressed mood) and somatic anxiety (items 8-14: muscular, sensory, cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic symptoms, and behavior at interview) based on a structured clinical interview.

Score Each Item 0–4

Each item is rated on a 5-point scale: 0 = absent, 1 = mild, 2 = moderate, 3 = severe, 4 = very severe. Total HAM-A score is the sum of all 14 items, ranging 0-56.

Interpret Total Score and Track Change

Score interpretation: ≤17 = mild; 18-24 = mild to moderate; 25-30 = moderate to severe; ≥31 = severe anxiety. A clinically meaningful change (MCID) is typically ≥7 points. Response = ≥50% reduction from baseline; remission = score ≤7.

Who Uses the HAM-A

Clinical Research Primary Endpoint

Clinical Researchers

HAM-A is required as a primary or secondary endpoint in many FDA clinical trial submissions for anxiolytic drugs and GAD treatments, providing a standardized clinician-rated measure of anxiety severity change.

Monitoring Treatment Response to Anxiolytics

Psychiatrists & Clinical Pharmacologists

Serial HAM-A administration quantifies response to SSRIs, SNRIs, buspirone, and benzodiazepines in clinical practice and trials, with response defined as ≥50% reduction and remission as score ≤7.

Psychiatric Baseline Assessment

Psychiatrists & Psychologists

HAM-A provides a comprehensive clinician-rated baseline of anxiety severity at treatment initiation, enabling objective measurement of subsequent improvement or deterioration across 14 specific symptom domains.

Comparing Anxiety Severity Across Time Points

Mental Health Clinicians & Researchers

As a standardized scale with established psychometric properties, HAM-A enables meaningful comparison of anxiety severity between baseline, mid-treatment, and end-of-treatment assessments in longitudinal clinical care.

FDA-Required Outcomes in Anxiety Trials

Regulatory Affairs & Drug Developers

The FDA requires HAM-A as a primary efficacy measure in most generalized anxiety disorder (GAD) clinical trials. It provides the regulatory standard against which anxiolytic drug efficacy must be demonstrated.

Pro Tips

HAM-A Must Be Clinician-Administered — Not Self-Report

HAM-A requires a trained clinician to rate symptoms based on interview and observation. Self-administration by patients produces invalid results. This distinguishes HAM-A from GAD-7, which is validated for patient self-report. Always clarify this distinction when implementing in clinical workflows.

GAD-7 Has Replaced HAM-A in Routine Clinical Practice

For routine primary care and outpatient mental health screening, GAD-7 (7-item self-report) has largely replaced HAM-A due to its self-report convenience, established screening thresholds, and equivalent sensitivity to change. HAM-A remains the standard in clinical trials and research settings.

Psychic vs Somatic Subscales Have Different Utility

HAM-A contains two subscales: psychic anxiety (items 1-6) measuring cognitive and psychological anxiety, and somatic anxiety (items 7-13) measuring physical symptoms. The somatic subscale may be more influenced by medical comorbidities; tracking both subscales separately helps identify whether improvement is primarily psychological or physical.

MCID Is 7 Points for Clinically Meaningful Change

A minimum clinically important difference (MCID) of approximately 7 HAM-A points is considered clinically meaningful in research contexts. Response is conventionally defined as ≥50% reduction from baseline, and remission as total score ≤7 or ≤10 depending on the study.

First-Line GAD Treatment: SSRIs and SNRIs Plus CBT

NICE guidelines and APA guidelines recommend SSRIs (sertraline, escitalopram, paroxetine) and SNRIs (duloxetine, venlafaxine) as first-line pharmacotherapy for GAD, combined with cognitive behavioral therapy (CBT). CBT alone or pharmacotherapy alone are both effective, but combination therapy produces the best outcomes.

Benzodiazepines: Short-Term Only

While benzodiazepines rapidly reduce anxiety, they are associated with tolerance, physiological dependence, cognitive impairment, and falls in elderly patients. Use only short-term (maximum 2-4 weeks) for acute anxiety while waiting for SSRIs/SNRIs to take effect, not as maintenance treatment.

Buspirone Is a Non-Dependence Alternative

Buspirone is an anxiolytic without dependence potential, useful for GAD maintenance treatment in patients where benzodiazepine risk is a concern. Onset is slower (2-4 weeks) than benzodiazepines — patients must be counseled about delayed effect to prevent premature discontinuation.

HAM-A Inter-Rater Reliability Requires Training

HAM-A inter-rater reliability is moderate (κ = 0.74-0.92) and requires assessor training for consistency, particularly in research contexts. Clinical trials typically require assessor certification and regular calibration sessions to maintain reliability. Untrained administration undermines data quality.

Common Questions About Your Results

Evidence-Based Methodology

HAM-A developed by Hamilton (Br J Med Psychol 1959). Clinician-rated; reliability κ varies (0.74-0.92). Widely used as primary endpoint in anxiety disorder clinical trials. GAD-7 (Spitzer et al., Arch Intern Med 2006) has largely replaced HAM-A in primary care due to self-report convenience. Response/remission criteria: Bandelow (Psychopharmacology 2006). NICE anxiety guidelines recommend SSRIs/SNRIs as first-line pharmacotherapy with CBT.

Clinical Content Trust

Last reviewed:: April 21, 2026
Guideline version:: General evidence framework v2026.04
Source set version:: Primary-source set v1

How to Interpret Your Result

Higher HAM-A totals indicate greater anxiety severity and can support treatment-intensity and follow-up planning.

When to Use This Tool

Use in clinician-led anxiety evaluation and longitudinal symptom tracking contexts.

Limitations

HAM-A requires interviewer consistency and can be influenced by overlapping somatic symptoms from medical conditions; it is not a standalone diagnostic test.

For related assessments, see GAD-7, GAD-2 and PHQ-9.

Disclaimer: This tool is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about your health.

Changelog

April 21, 2026 · trust-baseline
Clinical trust metadata enabled for this tool page with structured review/version fields.

Related Tools